Elevated plasma levels of endostatin are associated with chronic kidney disease

American Journal of Nephrology

Volumn 35, Issue 4, 2012, Pages 335-340

  Chen, Jing ^a,b   Hamm, L Lee ^a   Kleinpeter, Myra A ^a   Husserl, Fred ^c   Khan, Islam Enver ^a   Chen, Chung Shiuan ^b   Liu, Yanxi ^b   Mills, Katherine T ^b   He, Chuan ^b   Rifai, Nader ^d   Simon, Eric E ^a   He, Jiang ^a,b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY   (United States)

^c OCHSNER CLINIC FOUNDATION   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Albuminuria; Antiangiogenic factor; Chronic kidney disease; Endostatin; Estimated glomerular filtration rate

Indexed keywords

ALBUMIN; ENDOSTATIN;

ADULT; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

ADULT; AGED; ALBUMINURIA; CONFIDENCE INTERVALS; ENDOSTATINS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RENAL INSUFFICIENCY, CHRONIC;

EID: 84858980849     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000336109     Document Type: Article

References (26)

1. Levey AS, Coresh J: Chronic kidney disease. Lancet 2011;379:165-180.
2. Kronenberg F: Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 2009; 5: 677-689.
3. Lerman LO, Chade AR: Angiogenesis in the kidney: a new therapeutic target? Curr Opin Nephrol Hypertens 2009; 18: 160-165.
4. Maeshima Y, Makino H: Angiogenesis and chronic kidney disease. Fibrogenesis Tissue Repair 2010; 3: 13.
5. Kang DH, Anderson S, Kim YG, Mazzalli M, Suga S, Jefferson JA, Gordon KL, Oyama TT, Hughes J, Hugo C, Kerjaschki D, Schreiner GF, Johnson RJ: Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis 2001; 37: 601-611. (Pubitemid 32195301)
6. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE: Glomerular-specific alterations of VEGFA expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716. (Pubitemid 36278589)
7. Hovind P, Tarnow L, Oestergaard PB, Parving HH: Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int Suppl 2000; 75:S56-S61. (Pubitemid 30205441)
8. Kim NH, Oh JH, Seo JA, Lee KW, Kim SG, Choi KM, Baik SH, Choi DS, Kang YS, Han SY, Han KH, Ji YH, Cha DR: Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy. Kidney Int 2005; 67: 167-177. (Pubitemid 40019238)
9. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I, Lowik C, Timpl R, Olsen BR: Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 1999; 18: 4414-4423. (Pubitemid 29391251)
10. Hanai J, Dhanabal M, Karumanchi SA, Albanese C, Waterman M, Chan B, Ramchandran R, Pestell R, Sukhatme VP: Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 2002; 277: 16464-16469. (Pubitemid 34967659)
11. Hajitou A, Grignet C, Devy L, Berndt S, Blacher S, Deroanne CF, Bajou K, Fong T, Chiang Y, Foidart JM, Noel A: The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 2002; 16: 1802-1804.
12. O'Riordan E, Mendelev N, Patschan S, Patschan D, Eskander J, Cohen-Gould L, Chander P, Goligorsky MS: Chronic NOS inhibition actuates endothelial-mesenchymal transformation. Am J Physiol Heart Circ Physiol 2007; 292:H285-H294. (Pubitemid 46105189)
13. Stoessel A, Paliege A, Theilig F, Addabbo F, Ratliff B, Waschke J, Patschan D, Goligorsky MS, Bachmann S: Indolent course of tubulointerstitial disease in a mouse model of subpressor, low-dose nitric oxide synthase inhibition. Am J Physiol Renal Physiol 2008; 295:F717-F725.
14. Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa Y, Hirokoshi K, Sugiyama H, Yamasaki Y, Eguchi K, Makino H: Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 2005; 54: 2891-2903. (Pubitemid 41401084)
15. Futrakul N, Butthep P, Laohareungpanya N, Chaisuriya P, Ratanabanangkoon K: A defective angiogenesis in chronic kidney disease. Ren Fail 2008; 30: 215-217. (Pubitemid 351311487)
16. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Ships SG, Rochelle EJ: Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans. Circulation 2005; 111: 697-716.
17. Verbraecken J, Van de Heyning P, De Backer W, Van Gaal L: Body surface area in normalweight, overweight, and obese adults. A comparison study. Metabolism 2006; 55: 515-524.
18. Levey AS, Cores J, Greene T, Lesley AS, Zhang Y, Hendrickson S, Cusec JW, Van Lenten F, for the Chronic Kidney Epidemiology Collaboration: Using standardized serum keratinize values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254. (Pubitemid 46768608)
19. McGreevy KM, Lipsitz SR, Linder JA, Rimm E, Hoel DG: Using median regression to obtain adjusted estimates of central tendency for skewed laboratory and epidemiologic data. Clin Chem 2009; 55: 165-169.
20. Kitamoto Y, Tokunaga H, Tomita K: Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J Clin Invest 1997; 99: 2351-2357. (Pubitemid 27227711)
21. Tufro A, Norwood VF, Carey RM, Gomez RA: Vascular endothelial growth factor induces nephrogenesis and vasculogenesis. J Am Soc Nephrol 1999; 10: 2125-2134. (Pubitemid 29453490)
22. Masuda Y, Shimizu A, Mori T, Ishiwata T, Kitamura H, Ohashi R, Ishizaki M, Asano G, Sugisaki Y, Yamanaka N: Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 2001; 159: 599-608. (Pubitemid 32751090)
23. Shimizu A, Masuda Y, Mori T, Kitamura H, Ishizaki M, Sugisaki Y, Fukuda Y: Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol 2004; 15: 2655-2665. (Pubitemid 41103372)
24. Woolf AS, Yuan HT: Angiopoietin growth factors and Tie receptor tyrosine kinases in renal vascular development. Pediatr Nephrol 2001; 16: 177-184. (Pubitemid 32125170)
25. Futrakul N, Butthep P, Futrakul P: Altered vascular homeostasis in chronic kidney disease. Clin Hemorheol Microcirc 2008; 38: 201-207. (Pubitemid 351185407)
26. Yokoyama Y, Ramakrishnan S: Improved biological activity of a mutant endostatin containing a single amino-acid substitution. Br J Cancer 2004; 90: 1627-1635. (Pubitemid 38648249)